You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
秘魯恢復中國國藥集團疫苗臨床試驗
阿思達克 12-17 15:32
秘魯衛生部長表示,恢復中國國藥集團研發的新型冠狀病毒疫苗在當地進行臨床試驗。衛生部長馬塞蒂當地周三指,已經與國藥集團舉行幾次會議,決定恢復疫苗試驗。《華爾街日報》引述秘魯一名衛生部官員表示,醫生委員會發現該名志願人士出現的反應與疫苗無關。

秘魯衛生部日前表示,一名參與試驗的志願人士出現腿部力量下降等症狀,決定暫停有關疫苗測試。

國藥集團正在秘魯對大約1.2萬名志願人士進行疫苗臨床試驗,首階段試驗預期於未來幾天完成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account